Emergent BioSolutions (EBS) Accumulated Depreciation & Amortization (2016 - 2025)
Historic Accumulated Depreciation & Amortization for Emergent BioSolutions (EBS) over the last 17 years, with Q3 2025 value amounting to $72.3 million.
- Emergent BioSolutions' Accumulated Depreciation & Amortization fell 1268.12% to $72.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.3 million, marking a year-over-year decrease of 1268.12%. This contributed to the annual value of $108.8 million for FY2024, which is 1302.96% down from last year.
- Latest data reveals that Emergent BioSolutions reported Accumulated Depreciation & Amortization of $72.3 million as of Q3 2025, which was down 1268.12% from $48.9 million recorded in Q2 2025.
- In the past 5 years, Emergent BioSolutions' Accumulated Depreciation & Amortization registered a high of $143.3 million during Q4 2022, and its lowest value of $25.4 million during Q1 2025.
- Its 5-year average for Accumulated Depreciation & Amortization is $74.3 million, with a median of $72.3 million in 2025.
- Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first skyrocketed by 14710.58% in 2021, then plummeted by 1936.42% in 2024.
- Quarter analysis of 5 years shows Emergent BioSolutions' Accumulated Depreciation & Amortization stood at $123.8 million in 2021, then rose by 15.75% to $143.3 million in 2022, then fell by 12.7% to $125.1 million in 2023, then fell by 13.03% to $108.8 million in 2024, then tumbled by 33.55% to $72.3 million in 2025.
- Its Accumulated Depreciation & Amortization was $72.3 million in Q3 2025, compared to $48.9 million in Q2 2025 and $25.4 million in Q1 2025.